Rifapentine
- Generic Name
- Rifapentine
- Brand Names
- Priftin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H64N4O12
- CAS Number
- 61379-65-5
- Unique Ingredient Identifier
- XJM390A33U
- Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
- Indication
For the treatment of pulmonary tuberculosis.
- Associated Conditions
- Active Tuberculosis, Late phase Tuberculosis
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
Phase 3
Completed
- Conditions
- Pulmonary Tuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 1000
- Registration Number
- NCT00023335
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
Phase 2
Completed
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Anderson Clinical Research
- Registration Number
- NCT00002192
- Locations
- 🇺🇸
Hampton Roads Med Specialists, Hampton, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath